Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT)

HENDERSON, NV / ACCESSWIRE / March 22, 2019 / Many high-profile companies in the cannabis market have posted incredible gains since start of 2019 and this trend looks to continue.

The race to profit from the booming marijuana market has led to massive share-price increases for many companies in the industry. Many of these players look like they may have topped out, but we're looking for the next potential cannabis breakout play.

The most promising opportunity we found is THC Therapeutics, Inc. (THCT). THCT said the US patent office has accepted ALL 20 claims for their herb dryer the dHydronator, which can reduce moisture content of Cannabis to 10% in only 10-14 hours. The dHydronator® also destroys harmful surface contaminants & pathogens. Start your research today.

Today we are highlighting: THC Therapeutics, Inc. (THCT), Green Thumb Industries, Inc. (GTBIF), Aurora Cannabis (ACB), Zynerba Pharmaceuticals, Inc. (ZYNE) and Cara Therapeutics (CARA).

THC Therapeutics, Inc. (THCT) (Market Cap: $75.653M Share Price: $5.75) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested Cannabis and herbs. THCT's product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings.

As we mentioned earlier, the US patent office has accepted ALL 20 claims for The dHydronator®. This is Big News on THC Therapeutics, Inc. (THCT).

Green Thumb Industries, Inc. (GTBIF) (Market Cap: $693.535M; Share Price: $15.39342), a national cannabis consumer packaged goods company and owner-operator of the high-growth national retail chain RISEâ„¢, announced that it will hold a conference call on Tuesday, April 9, 2019 at 5:00 pm ET following the release of its fourth quarter and full year 2018 financial results after market close. Recently, the firm had also signed an agreement to acquire For Success Holding Co., the owner of Beboe-branded cannabis products. The purchase of the Los Angeles-based company will allow Green Thumb to expand its premium products section in accordance with the company's long-term expansion strategy.

_______

Aurora Cannabis (ACB) (Market Cap: $9.421B; Share Price: $9.30) announced earlier this month that the company had appointed Nelson Peltz as a Strategic Advisor. Mr. Peltz and Aurora will work collaboratively and strategically to explore potential partnerships that would be the optimal strategic fit for successful entry into each of Aurora's contemplated market segments. Mr. Peltz will also advise on the Company's global expansion strategy. Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain.

_______

Zynerba Pharmaceuticals (ZYNE) (Market Cap: $124.134M; Share Price: $5.89), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the fourth quarter and year ended December 31, 2018 and provided an overview of recent operational highlights. Armando Anido, Chairman and Chief Executive Officer of Zynerba, commented on the results, "the fourth quarter of 2018 was a period of strong clinical and corporate momentum, as we achieved our remaining 2018 milestones and positioned ourselves well for a watershed year in 2019. We continued enrollment into CONNECT-FX, our pivotal trial of Zygelâ„¢ in Fragile X Syndrome, and completed enrollment in BELIEVE 1, our Phase 2 trial in Developmental and Epileptic Encephalopathies. We also initiated the BRIGHT trial, which will evaluate Zygel in Autism Spectrum Disorder and are on track to initiate a Phase 2 trial in 22q11.2 Deletion Syndrome in the second quarter of 2019."

_______

Cara Therapeutics, Inc. (CARA) (Market Cap: $768.41M; Share Price: $19.43), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting peripheral kappa opioid receptors, announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2018. Derek Chalmers, President and Chief Executive Officer of Cara Therapeutics, commented, "we anticipate 2019 to be a transformative year for the Company with significant clinical readouts expected from both pivotal Phases 3 trials of KORSUVAâ„¢ Injection, and from our Phase 2 trial of Oral KORSUVAâ„¢ in pre-dialysis patients with CKD-aP. We also expect to broaden our clinical pruritus program for Oral KORSUVAâ„¢ with the initiation of Phase 2 trials in both liver disease and dermatological conditions, including atopic dermatitis."